GSK plc (GSK) announced that the European Medicines Agency (“EMA”) has accepted its application seeking approval for the expanded use of its cancer drug Jemperli (dostarlimab). The application is seeking approval for Jemperli plus chemotherapy to treat all adult patients with primary advanced or recurrent endometrial cancer. Pending review by the EMA’s Committee for Medicinal Products for Human Use, a decision from the European Commission is expected in the first half of 2025. Jemperli is currently approved ...